These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1, GIP, and glucose – leading to a combined effect. Bot